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Restricted T cell V repertoire in renal allografts during acute and
chronic rejection. Allo-MHC specific antigen recognition might not only
be involved in acute, but also in chronic rejection. The clonotypic
specificity of the T-cell receptor to recognize allo-MHC is located in the
variable (V) a and /3 chain. A restricted T-cell receptor repertoire could
support an immunological basis for chronic rejection. The novel feature of
this study is that the Vp repertoire was assessed in ongoing chronic
rejection before end-stage renal failure and in acute rejection. V/3s ito 20
were quantitated by PCR in PBMC and biopsies of rejecting renal
allografts. The V/3 pattern in PBMC demonstrated a polyclonal distribu-
tion. However, the intragraft V/3 repertoire was restricted to 1 to 3
dominant V/is and highly individual in 9 of 12 patients. Number and type
of the HLA mismatch and the time interval between transplantation and
biopsy did not correlate to the V/3 distribution. The individual response is
attributed to genetic predisposition factors of the recipient. Therefore, the
restriction of the V/i repertoire indicates allo-MHC dependent immune
processes not only in acute, but also in ongoing chronic rejection.
Tailor-made antibodies against dominant V/3s might offer specific individ-
ual immunosuppression in treating both acute and ongoing chronic
rejection.
Acute allograft rejection is mediated by T cells recognizing
allo-MHC/peptide complexes. Therefore, short-term survival in
renal transplantation was improved by better HLA typing and
more efficient immunosuppression [1]. No impact was achieved on
long-term graft loss. However, Eurotransplant data also show a
beneficial effect of HLA-matching for class I and II, UNOS data
only for HLA class I on long-term graft survival [2, 31, and the
number of acute rejection episodes seems to predict long-term
outcome [4]. Since chronic rejection is a major contributor to
long-term graft loss, HLA incompatibilities might present the
immunological link between acute and chronic allograft rejection.
The pathogenesis of chronic rejection is not well understood.
Immune-mediated graft injury is proposed among other risk
factors [5, 61. The vascular endothelium seems to be an important
target for the recipient's immune response [7]. Prominent vascular
abnormalities are consistent histopathological findings. Cellular
infiltrates were detected in chronic vascular lesions [81. Endothe-
hum-associated antigen systems include the HLA class I and 11
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antigens and non-MHC (minor) histocompatibility antigens [9,
10]. The expression of MHC class II on endothehial cells is
up-regulated by cytokines [11—131.
In this context we hypothesize an immunological basis for
chronic rejection in that T-cell mediated specific antigen recogni-
tion of allo-MHC and of antigens unique to the endothehium plays
a pivotal role not only in acute, but also in chronic rejection.
The specific recognition of antigens is exerted by the T cell
receptor, a heterodimeric, immunoglobulin-like surface molecule
composed of the a and /3 chains. The clonotypic TCR specificity
is located in the variable region of these two chains (Va and V/i)
[14]. Restricted TCR repertoires have been shown in response to
antigeneic peptides for various autoimmune diseases [15—18].
Compared to any particular antigen/self-MHC combination a
much higher percentage of T cells (1 to 10%) is activated by the
unrestricted number of possible allo-MHC/peptide combinations
in direct and indirect allorecognition [19—21]. Although one might
predict an involvement of a broad TCR repertoire, alloreactivity
has been controversially characterized by selective as well as
polyclonal TCR V usage. Shifts towards restriction over time with
changing antigen specificities have been demonstrated in cultured
T cells [221. DR1-reactive T cell lines derived from renal ahlografts
started out as a heterogeneous population, but developed V/38
predominance after repeated exposure to the antigen [23]. How-
ever, in vitro T cell clones distinguishing microvariations of
HLA-DR1 preferred the same V, but different J regions, indicat-
ing diversity of the TCR [24—26]. We have recently shown that in
MLRs with defined HLA-mismatch constellations, the V/i usage
was restricted and highly individual after seven days [27]. Frisman
et a! noticed the recurrence of dominant V/is in serial cardiac and
renal allograft biopsies, and Datema et al found recent recruit-
ment of donor-specific cytotoxic T cells only at the time of
rejection [28, 29]. In contrast, others have demonstrated a poly-
clonal V/i distribution in T cell lines from rejecting allografts [30,
31]. To date two in vivo studies (amplifying the TCR repertoire
from graft biopsies unbiased by culture techniques) revealed a
heterogeneous Va usage in acute rejection and end-stage graft
failure due to chronic rejection [32], a polyclonal V/i distribution
in earlier acute and chronic rejection [331. Taken together these
data are conflicting because of different start up material analyzed
at different time intervals post-allo-MHC stimulation.
The study presented here is unique in that we are the first to
investigate the V/i repertoire in vivo in ongoing chronic rejection
occurring two to seven years post-transplant, long before the loss
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Table 1. Selected patients classified by the type of rejection
Serum
Patient
HLA mismatch
A/B/DR
Rejection
histologically
creatinine
pinol/liter
Interval from
Tx to BX days
KY 1,-/17,-/-- acute 118 60
AN unknown acute 322 48
SJ 30,-/18,-/-,- acute 308 33
KK 1,2/37,-/13,- acute 337 336
DH 1,3/-,-!-,- acute 442 7
FH 30,-/-,-/-,- acute 272 111
KG 1,2/38,60/7,- chronic 288 1288
KA 24,26/40,-I-,- chronic 214 2587
SP 2,30/62,-I-,- chronic 396 1407
SM 31,-/-,-/12,- chronic 449 712
WR 25,-/49,-/-,- chronic 472 1937
TG 2,-/35,-/1,- chronic 268 872
of graft function. Acute rejection occurred mainly in the first three
months post-transplantation comparable to other studies. Allo-
graft function was impaired to the same degree in both groups.
Vs 1 to 20 were assessed by semiquantitativc PCR. A limited
TCR repertoire with dominant Vs could support the postulated
immunological basis for chronic rejection and offer the possibility
for selective immunosuppression for both entities, acute and
ongoing chronic rejection.
Methods
Patient specimens
It is the policy of our institution to perform ultrasound guided
needle biopsies in all patients with deteriorating graft function at
the time of clinically suspected rejection, after informed consent.
The tissue was divided for histology and snap frozen for PCR
analysis. Twelve biopsies of HLA mismatched (scro-typing) Ca-
daveric kidney allografts were classified into acute (N 6) and
chronic (N = 6) rejection on histological (Banif classification) and
clinical grounds not differing from each other. The time interval
between transplantion and biopsy amounted to a median of 54
days (range 7 te 336 days) in acute rejection, and 1348 days (range
712 to 2587 days) in chronic rejection. Mean serum creatinine was
300 106 in acute and 348 106 imol/liter in chronic rejection.
All patients with chronic rejection developed gradually deterio-
rating graft function, whereas patients with acute rejection im-
proved after treatment with OKT3. The immunosuppressive
regimen consisted of methylprednisolone and cyclosporine A at
the time of biopsy. At the same time PBMC were collected. Serial
biopsies as well as biopsies showing no signs of rejection were not
available. The patients' data are summarized in Table 1.
Samples of normal renal tissue from nephrectomies served as a
control group. One patient underwent nephrectomy because of
hyperacute rejection. Multiple biopsies were obtained to control
whether the T cell repertoire in the biopsy was representative for
the whole allograft.
Isolation of PBMC
PBMC were separated by density gradient centrifugation via
Ficoll Hypaque (Seromed, Berlin, Germany) according to stan-
dard procedures.
RNA extraction and reverse transcription
Total RNA was extracted following a modified protocol de-
scribed by Chomczinsky and Sacehi [341. To enlarge the yield of
total RNA 3 t-RNA from yeast (Promega, Heidelberg, Ger-
many) were added for copreeipitation in biopsy samples.
First, strand eDNA synthesis was performed with 330 ng
random hexamers (Sigma, Deisenhofen, Germany) in 50 mM
Tris-HCI (pH 8.3), 18.8 mM KC1, 0.75 mM MgC12, 0.01 M DTT, 0.5
M dNTP, 80 U RNasin (Promega) and 600 U moloney murine
leukemia virus reverse transcriptase (M-MLV RT; GTBCO, Egg-
enstein, Germany) and 10 to 30 ig RNA. After linearizing the
secondary structure of the RNA, first DNA strand synthesis was
performed at 42°C for one hour and RT was heat inactivated.
Amplification of cDNA by PCR
Each V product was coamplified with Ca to control for the
amount of start up RNA. The 5' sense primers reported by Choi
et al for amplification of specific V families and the 3'Cp
AACTGGACTFGACAGCGGAAGTGG generated product
sizes of 490 to 540 bp [35]. The Ca primers (5'Ca GAACCCT-
GACCCTGCCGTGTACC and 3'Ca ATCATAAAT1CGGG-
TAGGATCC) were selected to amplify a 604 bp product [36]. For
each specimen the relative amplification efficiency and the limits
of exponential coamplifleation for both products were determined
by different cycle numbers as described by Chelly et al [371. The
eDNA sample was devided into 22 aliquots. Contamination of the
samples with genomic DNA was excluded. The PCR reaction
mixture in 50 d contained 20 mrvi Tris-HC1, 16 mvt (NH4)2 SO4,
2 mrvi MgCI2, 150 .tg/ml BSA (Sigma), 0.05 mM dATP, dTTP,
dGTP, dCTP (Promega) and 0.2 .rg of each primer 5'V/3, 3'Cf3, 5'
and 3' Ca and Taq polymerase (AGS, Heidelberg, Germany). The
mixture was overlaid with light mineral oil. The Perkin Elmer
thermocycler (Perkin Elmer, Ueberlingen, Germany) was pro-
grammed as follows: denaturing of DNA at 94°C for one minute,
annealing at 55°C for one minute, elongation at 72°C for one
minute, cycle number according to the amplification efficiency. In
the control group GAPDH (primer 5 'TGAAGGTCGGAGT-
CAACGGAmGG, 3 'GACCACCTGGAGTACCGGGTGTA-
C-983 bp) and Ca were coamplified to assess the T cell content in
normal renal tissue. The PCR followed the same protocol with
annealing at 60°C. PCR products were size-fractioned on a 1.8%
agarose (Serva, Heidelberg, Germany) gel and transferred to a
Hyhond N filter (Amersham, Braunsehweig, Germany). A spe-
cific eDNA probe recognizing a homologous region of Cf31 and
Cp2, and the V products, respectively, and a Ca specific internal
oligonucleotide were randomly primed or end labeled with fiavin-
UTP. Hybridization and detection of hybrids was performed
according to the enhanced chemiluminescense method (Amer-
sham). After overlaying the filter with the appropriate detection
agents autoradiography was performed.
Quantitation of vp families by densitometiy
The amount of the amplified products was assessed by the
Molecular Dynamics Laser densitometer and the software Image-
quant. The absorption of the V band was compared to the one
of the Ca band—representing all T cells—of the same lane. The
percentage of each V was calculated by the following formula:
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Fig. 1. Autoradiograph of the V13 repertoire in the kidney allograft of patient KY assessed by PCR as a coamplifi cation of VpJ-20 and Ca representing all T
cells.
abs. Vp X
abs. Ca ><
%Vpl-20 = x 100
abs. V 1-20
abs. Ca 1-20
Each V was expressed as a percentage of the total amount of
all amplified Vps representing 100%. The percentage of =>15%
was considered a dominant V family according to the accuracy of
the chosen method of PCR.
Results
T cell content in normal renal tissue
Samples of normal renal tissue (N = 3) served as a control to
establish that T cell infiltrates are only found in rejecting, but not
in normal kidneys. Coamplification and separate amplification
from GAPDH and Ca or C/3 revealed no T cell RNA.
The T cell vp repertoire in rejecting renal allografis
The T ccli infiltrate in a single obtained biopsy specimen was
representative of the whole kidney, since three graft biopsies from
different locations in one nephrectomized patient revealed the
identical V/3 repertoire.
The autoradiograph of patient KY serves as an example to
demonstrate the V expression assessed by PCR (Fig. 1). Ca (604
bp) was expressed equally in all lanes, whereas V 1 to 20 were
seen in varies degrees with V2 and 17 reaching the highest
percentage. Some Vs were not detectable at all.
Characteristics of the patients are depicted in Table 1.
Acute rejection. The V repertoire was restricted to 1 to 3
dominant V families in 5 of 6 patients undergoing acute rejec-
tion (Fig. 2). Patient KY showed a broader V response pattern
than the other patients. The response was individual and not
correlated to a certain HLA-mismatch, the number of presented
HLA-mismatches or the time interval in which acute rejection
occurred [patient DH (7 days) and KK (336 days) with equally
restricted V/3s1.
In detail, in patient KY (A) Vf32 reached 14% and Vf317 12%
reflecting a preferred, but not clearly restricted V3 usage. Patient
AN (B) showed Vp13.1 as the dominant family with 20%. V6
and 7 participated with 12% and 13%. Patient SJ (C) demon-
strated a predominance of V2 with 20%, V7 reached 16%.
Patient KK (D) presented with a dominant V3 with 24%
followed by Vj37 (13%) and Vj38 (12%). Patient DH (E) ex-
pressed Vf32 (24%), V7 (24%), and Vf314 (19%) predominantly.
Patient FH (F) revealed the most restricted V pattern with Vf314
reaching 68%.
Chronic rejection. The V repertoire was limited to 1 to 3 V
families in chronic rejection in 4 of 6 patients (Fig. 3). The
response was as individual as in acute rejection, no specific
correlation to certain HLA-mismatches or the time point when
chronic rejection was diagnosed was demonstrated. However, in
two patients a polyclonal response was seen (Fig. 3 A, B). Both
were characterized by the highest number of HLA mismatches in
this group.
In detail, patient KG (A) and patient KA (B) showed no
predominance of any Vp. A uniform polyclonal distribution was
seen. In patient SP (C) V2 was found with 32%. Patient SM (D)
expressed V/37 nearly exclusively with 60%. Patient WR (E)
revealed three dominant V/3s, Vj36 with 37%, V/32 and Vf37 each
with 21%. Patient TG (F) demonstrated a T cell response
restricted to V/314 rising to 88%.
T cell V repertoire in PBMC
The V pattern was determined in four patients with acute and
five with chronic rejection. All Vj3s were detectable, no dominant
response was seen (data not shown). The restricted Vp distribu-
tion in the allograft was not reflected in PBMC in both groups.
Independent of the number of HLA mismatches the pattern was
polyclonal.
The percentage of Vf3s in PBMC was deducted from the
percentage of V/3s in the corresponding biopsies. Therefore,
contamination of PBMC in renal vasculature did not influence the
V pattern in biopsy specimens.
Additionally, the number of alleles encoding each V did not
shape the peripheral or intragraft V/3 repertoire, which was
excluded by the calculation of mean values of each V [38].
Discussion
We describe a restricted, highly individual V repertoire in
renal allografts in 9 of 12 patients during acute and ongoing
chronic rejection. A correlation to type and degree of HLA-
mismatches or to the time interval between transplantation and
biopsy was not seen. The V distribution in PBMC was polyclonal
in all patients.
The novel feature of this in vivo study is the restricted TCR
usage in ongoing chronic rejection long before loss of graft
function occurring two to seven years post-transplantation with a
mean creatinine of 348 rmol/liter. In contrast, Krams et al only
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analyzed end-stage chronic rejection samples from patients un-
dergoing nephrectomy because of end-stage graft failure and
found a heterogeneous Va response in vivo [32]. Polyclonal V
repertoires were also demonstrated in T cells generated from
transpiantectomies by others [30, 311. Pavlakis, Lipman and Strom
unfortunately did not characterize their cohort of chronic rejec-
tion patients clearly concerning the time interval between trans-
plantation and biopsy [331. In one patient with serial biopsies
showing chronic rejection at two months and at transplant ne-
phrectomy 14 months later, the V repertoire was diverse on both
occasions. Therefore, one time point reflects early occurring
chronic rejection and the other end-stage graft failure, revealing a
different velocity in the process of chronic rejection as compared
to our patients with slower progression of chronic rejection. In
concert with these studies, we believe that in chronic rejection the
VJ3 repertoire might start with diversity [33], but develops pre-
ferred usage of TCR at a certain time during slowly-deteriorating
graft function, before showing heterogeneity at end-stage graft
function again [31—33]. Allo-MHC inducible via cytokine release
on endothelial smooth muscle cells and on renal tubular cells
might govern the TCR restriction and perpetuate ongoing chronic
rejection. Since chronic rejection is characterized by slowly pro-
gressing fibrosis of the vasculature and interstitium, at end-stage
graft failure the antigen presenting endothelium as well as the
renal tuhuli are substituted by fibrosis with decreasing surface
area to express allo-MHC explaining the unrestricted Vp pattern
at that time. Time courses on the V13 pattern in chronic rejection
have not been described.
In acute rejection a dynamic, time-dependent development of
TCR restriction has been demonstrated in cultures of graft-
infiltrating lymphocytes. In serial cardiac allograft biopsies, recur-
rent V13s indicative of the persistence of a "favored" clone and
time-dependent (days 9 to 129 post-transplant) shifts towards an
accumulation of dominant clones evident only at the time of
rejection were detected [28, 29]. In a bone marrow transplant
recipient expanded clones were replaced by other clones when
graft-versus-host disease occurred [39]. In vivo studies in a rat
cardiac allograft model on freshly isolated T cells demonstrated
that a selective V13 repertoire is used in initiating alloreactivity
and becomes less restricted as rejection with non-specific inflam-
matory events and fibrosis progresses [40]. This is in agreement
with the restricted V distribution presented here in biopsies
obtained immediately when rejection was suspected. However,
others have found a diverse V repertoire in T cell lines from
acutely rejecting grafts becoming restricted after continuous an-
tigen stimulation, though in vitro [22, 23, 31]. The in vivo results
from Paviakis et al revealed a polyclonal V usage in acutely and
a more restricted one in non-rejecting grafts applying the same
methodology as here [33].
Acknowledging these findings in the context of our data, we
conclude that the timing of the TCR repertoire analysis during
chronic and acute graft rejection exerts a critical influence on the
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Fig. 2. Intragraft frequency of TCR V 131-20 gene usage in six patients with acute rejection in renal allograft biopsies. The results are expressed as a
percentage of all amplified V13 families. Dominance was defined as => 15%. (A) Patient KY; (B) AN, (C) SJ, (D) KK, (E) DH, (F) FIT. Apart from
(A), all patients (B—F) showed an individual V13 repertoire restricted to 1 to 3 dominant V13 families.
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results obtained. This could also explain the polyclonal responses
in 3 of 12 patients. Longitudinal studies on the intragraft TCR
development including indicators of cytotoxicity (such as gran-
zyme B) especially in vivo over longer periods of time in acute,
chronic, and no rejection are required to elucidate the time-
dependent appearance and functional significance of dominant
clones.
The asymmetrical use of TCR cs and /3 genes has been reported
in an in vitro alloreactivity system and in a cardiac allograft model
characterized by V/3 restriction, but diverse Va usage [41, 42].
Thus, the limited V/3 repertoire found here is not contradictory to
the in vivo study of Krams et al showing a polyclonal Va pattern
in acutely and chronicly rejecting renal allografts [32]. Many
different T cell populations can use the same V/3gene while using
different TCR Va gene segments, as well as different /3 chain D
and J segments [24, 25]. The finding of a restricted V/3 repertoire
should be considered as a first approximation of a limited clonal
response in rejection.
The intragraft selection of dominant V/3s was strictly individual
and did not correlate to the specific HLA-mismatch alone (such as
HLA-A1, 2 and 30 were present in some patients as listed in Table
1). Previously we have shown that in MLRs with defined HLA-
mismatches the Vf3 repertoire was not as obviously shaped by the
allo-MHC alone, but also by different predeterminations of the T
cell repertoire of the responder [27], such as genetic influences
[43, Diverse, but non-random V/3 repertoires with some
overlap between individuals and highly diverse CDR3 regions
were detected in response to HLA-DR1 [25]. The allo-mismatch
driven Vf38 restriction of HLA-DRI shown by Hand, Hall and
Finn was assessed in only two responders obscuring individual
influences [23]. The degree of HLA-mismatches was not strongly
associated with diversity [polyclonal in patient KG (MM:2-2-1),
KA (MM:2-1-0) with chronic and in KY (MM:1-l-0) with acute
rejection] as shown by others [31, 33].
This study is the first to state that the V13 TCR repertoire is
restricted and individual in acute and ongoing chronic renal
allograft rejection in vivo before reaching end-stage graft failure.
It supports the notion that chronic rejection is in part immuno-
logically allo-MHC mediated. det.ction of TCR restriction is
influenced by the timing of the biopsy. At that moment of limited
clonal response tailor-made antibodies or TCR peptides against
dominant V/3s could provide an individual strategy for selective
immunosuppression targeting only those T cells promoting both
acute or ongoing chronic rejection. These agents have been
successfully applied in allorecognition in vitro and in multiple
sclerosis patients [45, 46].
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Appendix
Abbreviations are: bp, base pair; Bx, biopsy; BSA, bovine serum
albumin; C, constant region of the T cell receptor; eDNA, copy DNA;
CDR, complementary determining region; dNTP, desoxynucleotide
triphosphate; HLA, human leukocyte antigens; MHC, major histocompat-
ibility complex; MLR, mixed lymphocyte reaction; MM, mismatch; M-
MLV, moloney murine leukemia virus; PBMC, peripheral blood mono-
nuclear cells; PBS, phosphate buffered saline; PCR, polymerase chain
reaction; SDS, sodium dodecyl sulfate; SSC, saline sodium citrate; Taq,
thermus aquaticos polymerase; TCR, T cell receptor; Tx, transplantation;
V, variable region of TCR.
Reprint requests to Claudia Barth, M.D., Medizinische Klinik IV Nephrol-
ogy, University hospital Koeln, Josef -Stelzmann SIr. 9, 50924 Koeln, Ger-
many.
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